Home

Atlas Venture Associates IX, LLC

CIK 1671207 · last filed 2020-12-21

Atlas Venture Associates IX, LLC is a corporate insider who has filed 6 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing shows the insider sold $92.3M of SURF on Dec 21, 2020. Across all open-market trades the lifetime net is −$85.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $47.5M across reported positions. The firm reports its address in Boston, MA. 11 SEC filings were submitted jointly with Atlas Venture Fund IX, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$47.52M

Companies

3

Total Filings

6

Lifetime Open-Market Net

-$85.01M

Filer Profile

Reported Address
56 WAREHAM STREET, FLOOR 3
BOSTON, MA 02118
Phone
(617) 588-2694
State of Incorporation
DE
Related Filers
Atlas Venture Fund IX, L.P. — 11 joint filings, latest 2020-12-21
Atlas Venture Associates VIII, Inc. — same reported address
Atlas Venture Associates VIII, L.P. — same reported address
Atlas Venture Fund VII L P — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Surface Oncology, Inc. (SURF) Delisted 10%+ Owner 2,945,453 $1.07 $3.15M -$87.81M 2 2020-12-21
Cogent Biosciences, Inc. (UMRX) Delisted 10%+ Owner 3,267,483 — — $3.39M 1 2018-04-03
NTLA 10%+ Owner 3,729,788 $12.74 $47.52M -$587.7K 3 2017-03-13

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-12-21 Surface Oncology, Inc. (SURF) Delisted Sell (S) −5,100,000 -$92.31M EDGAR
2018-04-23 Surface Oncology, Inc. (SURF) Delisted Mixed +9,845,451 $4.50M EDGAR
2018-04-03 Cogent Biosciences, Inc. (UMRX) Delisted Mixed +10,084,605 $3.39M EDGAR
2017-03-13 NTLA Sell (S) −42,264 -$587.7K EDGAR
2017-03-07 NTLA Other (J) −2,100,000 $0 EDGAR
2016-05-11 NTLA Conv (C) +13,289,364 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.